Qiagen (NYSE:QGEN) Sees Large Volume Increase – Time to Buy?

Qiagen N.V. (NYSE:QGEN) shares saw strong trading volume on Wednesday . 3,534,944 shares were traded during mid-day trading, an increase of 29% from the previous session’s volume of 2,735,731 shares.The stock last traded at $54.6950 and had previously closed at $55.45.

Trending Headlines about Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Zacks Research nudged its Q1 2027 EPS estimate up to $0.68 from $0.67, a small positive signal for near‑term earnings expectations that may be helping support the stock.
• Neutral Sentiment: Media pieces note that analysts are “conflicted” on Qiagen, highlighting mixed buy/hold/sell views rather than a consensus directional change; this increases focus and trading but doesn’t force a clear fundamental shift. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Neutral Sentiment: A similar roundup notes mixed analyst views again (adds visibility and trading interest but not a unified directional signal). Analysts Conflicted on These Healthcare Names
• Negative Sentiment: Zacks Research lowered multiple quarterly EPS estimates (including Q3 2027 and Q4 2026) and trimmed near‑term forecasts overall — a signal that analysts see some softening in near‑term profit trends. Consensus full‑year EPS remains around $2.26, but the downward quarterly revisions are a near‑term negative for sentiment.
• Negative Sentiment: Deutsche Bank downgraded Qiagen, a direct negative from a major sell‑side firm that can pressure sentiment and weighing on shares despite the mixed analyst picture. Deutsche Bank downgrades Qiagen NV (QGEN)

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Barclays reiterated an “overweight” rating and set a $57.89 price objective (up previously from $55.79) on shares of Qiagen in a research report on Monday, December 15th. UBS Group reiterated a “neutral” rating on shares of Qiagen in a report on Wednesday. Deutsche Bank Aktiengesellschaft lowered Qiagen from a “buy” rating to a “hold” rating and raised their price target for the stock from $52.00 to $54.00 in a research note on Thursday. Citigroup downgraded shares of Qiagen from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $57.89 to $52.63 in a research note on Thursday, December 11th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $53.04.

Qiagen Stock Up 2.4%

The stock has a fifty day moving average price of $48.88 and a 200-day moving average price of $49.52. The firm has a market cap of $11.73 billion, a PE ratio of 28.68, a PEG ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $532.58 million for the quarter, compared to analysts’ expectations of $525.68 million. During the same period in the previous year, the company posted $0.60 earnings per share. Qiagen’s revenue was up 6.2% compared to the same quarter last year. Research analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank boosted its position in shares of Qiagen by 1.8% in the second quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after buying an additional 209 shares during the period. Atria Investments Inc increased its position in shares of Qiagen by 2.9% during the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after acquiring an additional 218 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Qiagen by 9.4% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock valued at $123,000 after purchasing an additional 221 shares in the last quarter. Yousif Capital Management LLC grew its holdings in Qiagen by 3.7% during the 2nd quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock worth $301,000 after acquiring an additional 222 shares in the last quarter. Finally, Johnson Investment Counsel Inc. grew its stake in Qiagen by 0.4% in the third quarter. Johnson Investment Counsel Inc. now owns 57,359 shares of the company’s stock worth $2,563,000 after purchasing an additional 240 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.